Gary Gottesman, MD
Clinical Genetics (M.D.) · Saint Louis, MONPI 1447269444
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,517 of the $28,287 with a category attached, or 90.2%. Kyowa Kirin, Inc. accounts for 60.9% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $14,764, more than ten times the $35 reported in 2019.
Across 39 payments — averaging $725.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$17K
- Ultragenyx Pharmaceutical Inc.$11K
- AstraZeneca$18
Across 365 payments — averaging $5553.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$2M
- AstraZeneca$34K
What the payments were for
- Consulting fees$25,51790%
- Travel & lodging$1,8877%
- Food & beverage$8533%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 24 | $17,237 |
| Ultragenyx Pharmaceutical Inc. | 14 | $11,032 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 45 | $1,249,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $17,237 | $1,249,97245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical genetics (m.d.) providers in Missourion file to place this against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Saint Louis
- Patricia DicksonSaint Louis$4K
- Dorothy GrangeSaint Louis$2K
- Hoanh NguyenSaint Louis$1K
- Maria Duque LasioSaint Louis$787
- Marwan ShinawiSaint Louis$229
- Katherine KingSaint Louis$63
- Diana GraySaint Louis$20
- Eric RushKansas City$779K
- Majed DasoukiKansas City$2K
- Angela LeeKansas City$490
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.